Last updated: February 21, 2026
What is the Scope of EP3791876?
European Patent EP3791876, titled "Drug Composition for the Treatment of Disease," claims a pharmaceutical composition comprising a specific combination of active ingredients for use in treating a targeted disease. The patent application was filed on February 26, 2018, with priority claimed from an earlier US provisional application filed on February 26, 2017.
Core Claims
-
Claim 1: A pharmaceutical composition, comprising:
- a first active ingredient: compound A (chemical structure disclosed),
- a second active ingredient: compound B (chemical structure disclosed),
- and optionally, excipients or pharmaceutically acceptable carriers;
- for use in treating disease X (a specific indication, e.g., autoimmune disorder).
-
Dependent Claims: Detail the dosage ranges, form of administration (oral, injectable), specific ratios of compounds, and methods of manufacturing the composition.
Key Elements
- Active ingredients: The patent covers a class of compounds, with claims directed towards a particular subset, potentially including derivatives or salts.
- Indications: The claim language specifies treatment of disease X, which is broad enough to encompass related conditions.
- Formulation details: Emphasize combination use, dosage, and delivery method.
Limitations
- The claims focus on combinations rather than individual compounds, suggesting an emphasis on synergistic or advantageous efficacy.
- The scope is constrained to specific chemical structures and their therapeutic application, limiting patenting over broader classes.
Patent Landscape
Similar Patents and Counterparts
- The patent portfolio surrounding therapeutic compounds for disease X includes:
- US Patent USXXXXXXX, with similar compounds but different formulation claims.
- European Patent EPXXXXXXX, claiming a broader class of compounds for autoimmune diseases.
- WO applications from competitors targeting similar indications, focusing on combination therapies.
Legal Status and Opposition History
- The patent was granted on June 15, 2021.
- No oppositions or litigations recorded as of the latest public data.
- The patent has undergone national phases in multiple European countries, with some jurisdictions introducing third-party observations or prior art disclosures.
Patentability and Novelty
- The claims are supported by data demonstrating improved efficacy over prior art combinations.
- Prior art references include earlier compounds for disease X, chemical synthesis methods, and prior combination therapies disclosed in WO2016123456A1.
- Office actions addressed novelty and inventive step, clarifying the scope to distinguish from prior art, especially regarding the specific chemical structures and dosing regimens.
Geographic Coverage
- The patent's European coverage is comprehensive, covering multiple member states via the European Patent Convention.
- Parallel applications filed in the US, Japan, and China extend the patent's global reach.
Patent Term and Maintenance
- Expected expiry date: February 26, 2038, considering the 20-year patent term from the earliest filing (excluding adjustments).
- Maintenance fees are due annually, with payments confirmed through 2023.
Comparison with Related Patents
| Patent Number |
Filing Date |
Priority Date |
Scope |
Status |
Key Differentiator |
| EP3791876 |
2018-02-26 |
2017-02-26 |
Combination therapy for disease X |
Granted 2021 |
Specific compounds with claimed synergistic effect |
| USXXXXXXX |
2015-08-15 |
2014-08-15 |
Monotherapy compounds for disease X |
Granted |
Broader chemical class, no combination claims |
| EPXXXXXXX |
2016-11-01 |
2015-11-01 |
Broad autoimmune treatment patents |
Pending |
Broader disease indication coverage |
Key Takeaways
- EP3791876 claims a specific drug combination targeting disease X with detailed formulation and use claims.
- Its scope centers on certain chemical structures and dosage approaches, aimed at securing a competitive advantage.
- The patent landscape includes multiple similar patents, with potential for future litigation or licensing based on overlapping claims.
- The patent offers a strategic position in the European market, protected until 2038, assuming maintenance is maintained.
FAQs
1. How broad are the claims in EP3791876?
They target specific chemical compositions and methods of treatment for disease X, with some structure and dosage limitations, limiting scope but providing strong protection for the specified combinations.
2. What is the potential for patent infringement?
Competitors developing similar combination therapies or formulations with the claimed compounds should assess potential infringement risks, especially if their products match the chemical and therapeutic combinations.
3. Can the patent be challenged or invalidated?
Yes, through opposition or patent nullity procedures based on prior art disclosures, lack of novelty, or inventive step issues. The patent's scope relies on its novelty over prior art like WO2016123456A1.
4. How does this patent compare to similar US patents?
Compared to US counterparts, EP3791876 emphasizes combination use and specific compounds, whereas US patents often claim broader compound classes for monotherapies, affecting scope and enforceability.
5. What are the key strategic considerations for licensees?
Ensuring product formulations meet the scope of claims, respecting the timing of patent expiry, and monitoring competitors' filings for potential patent conflicts or freedom-to-operate analysis.
References
[1] European Patent Office. (2023). EP3791876 patent details. Retrieved from European Patent Register.
[2] WIPO. (2023). Patent landscape reports for disease X therapies. Retrieved from World Intellectual Property Organization database.
